ReviewPharmacoEconomics2008
Economic burden of psoriatic arthritis.
Review in PharmacoEconomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03442088 (An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature.Clinical rheumatology · 2016Pooled it
- Recent Advances in Smart Biomaterials for the Detection and Treatment of Autoimmune Diseases.Advanced functional materials · 2020Article
- Could Psoriatic Arthritis Be Easily Diagnosed from Current Suspicious Physical Findings in the Dermatology Clinic?Annals of dermatology · 2017Article
- Combining mechanism-based prediction with patient-based profiling for psoriasis metabolomics biomarker discovery.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2017Article
- Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis.BMC musculoskeletal disorders · 2016Observational
- Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.PharmacoEconomics · 2010Article
- Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.Rheumatology international · 2009Article
- Psoriatic arthritis: pharmacoeconomic considerations.Current rheumatology reports · 2009Article
- Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.Arthritis and rheumatism · 2009Article
- The treatment of psoriatic arthritis and inflammatory spondylitis.Current pain and headache reports · 2008Review
- The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic arthritis (PsA) is a chronic autoimmune disease characterized by inflammatory arthritis in association with skin psoriasis (Ps). PsA may show a heterogeneous and variable clinical course, with involvement of peripheral and axial diarthrodial joints, periarticular structures such as entheses, as well as the skin and nails. Evidence is increasing that affected patients can have significant radiographic joint damage, functional impairment, reduced quality of life (QOL) and long-term work disability. The economic burden of PsA can be considerable. There is an increasing interest in pharmacoeconomic evaluations in PsA, driven mostly by the introduction of highly effective but expensive biologic agents, particularly inhibitors of the proinflammatory cytokine tumour necrosis factor (TNF)-alpha. Treatment with TNFalpha inhibitors results in not only substantial improvements in signs and symptoms of arthritis, but also improvements in all distinct sites of the disease, such as axial arthritis, dactylitis, enthesitis and skin disease. There is a dearth of published pharmacoeconomic evaluations in the field of PsA. The notable clinical efficacy of the TNFalpha inhibitors needs to be factored into a comprehensive assessment of their value. Further analyses are needed to optimize the use of the new biologic agents in PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.